- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06185127
Dexmedetomidine-ketamine Combination Versus Fentanyl-midazolam During Bronchoscopy
Dexmedetomidine-ketamine Combination Versus Fentanyl-midazolam for Patient Sedation During Flexible Bronchoscopy: a Prospective, Single-blind, Randomized Controlled Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study design and population This randomized controlled trial of adult patients (age >18 years) scheduled for FB was conducted between September 2019 and May 2020 at the Respiratory Medicine Department of Athens Naval Hospital, Greece.
Exclusion criteria included: known or suspected allergy to any of the study drugs, renal impairment (serum creatinine > 2 mg/dL), hepatic impairment (liver enzymes > 2 times the upper limit of normal), seizure disorders, history of psychosis or bipolar disorder, hemodynamic instability (heart rate - HR < 50 bpm or systolic blood pressure - SBP < 90 mmHg), and critically ill patients. The study protocol was approved by the Ethics Committee of Athens Naval Hospital (act number 296/13.08.2019), and written informed consent was obtained from all participants.
Protocol Demographic data and medical history were reviewed at the presentation, and the vital signs were assessed and recorded.
Eligible patients were then randomly assigned to two groups:
- DK group: Dexmedetomidine solution of 1 μg/kg dissolved in 60 ml saline was administered over 15 minutes, followed by a maintenance dose of 0.5 μg/kg/h (continuous infusion). After the first 15 minutes, a bolus dose of 50 mg ketamine dissolved in 10 ml saline was given. An increase of 0.1 μg/kg in the infusion rate of dexmedetomidine was considered when necessary to optimize the level of sedation.
- MF group: Bolus doses of midazolam (5 mg midazolam dissolved in 10 ml saline; 2 ml of the solution or 1 mg midazolam per bolus, premedication dose of 2mg, induction dose of 2 mg) and fentanyl (100 μg / 10 ml; 5 ml of the solution or 50 μg fentanyl per bolus, induction dose of 50μg) were administered at 20-minute intervals in between and titrated as needed to obtain the desired sedation depth. No more than 12 mg of midazolam and 150 μg of fentanyl were administered.
The depth of sedation was quantified at the onset of drug infusion using the Observer's Assessment of Alertness/Sedation scale; a maximum score of 3 was considered optimal for starting FB. Bolus doses of dexmedetomidine (DK group) and midazolam (MF group) were administered when necessary to maintain the same target score. An anesthesiologist was present throughout the procedure to oversee and monitor the sedation protocol. Only the anesthesiologist and the nurse of the bronchoscopy suite were aware of the sedation regimen. The attending pulmonologist remained blind regarding the sedation protocol until the completion of the bronchoscopist satisfaction questionnaire (see below).
Lidocaine gel was placed at the nostril of entry before the procedure, and lidocaine (4 ml of 2% solution) was sprayed under direct vision through the bronchoscope for vocal cord anesthesia before entering the larynx. All participants (in both the MF and the DK group) were initially premedicated with 2 mg of midazolam for anxiolysis and perioperative amnesia 10 minutes before commencing the procedure. They also received oxygen at 2 L/min via nasal cannula and 0.9 NaCl i.v. at 8 ml/h throughout the procedure. Continuous monitoring included electrocardiography, oxygen saturation (SpO2), and automated non-invasive blood pressure recordings.
Outcomes The depth of sedation was evaluated using the Ramsay sedation scale [28] and the Riker sedation-agitation scale. Both tools provide quantitative measurements in the maximum and minimum sedation-agitation range during the procedure. Higher Ramsay and lower Riker scores signify deeper sedation levels.
Bronchoscopist satisfaction was measured with a Likert-scale tool answering the question "How satisfied are you with both the ease and outcome of the procedure?" as follows: 1 = not satisfied at all; 2 = somewhat satisfied; 3 = more satisfied with the procedural outcome; 4 = mostly satisfied with the outcome and somewhat with procedural ease; 5 = exceptionally satisfied with both procedural outcome and ease.
Patient satisfaction was evaluated by a short, custom-made questionnaire that included the following questions: 1) I was satisfied with the sedation administered for the procedure, 2) I felt pain and/or discomfort beyond my tolerance during the procedure, 3) I believe my needs were met during the procedure 4) I felt pain and discomfort after the procedure, 5) I would be willing to undergo a second procedure if the first did not yield adequate results. The responses were measured in a Likert scale format with values 1 = strongly disagree; 2 = disagree; 3 = neither agree nor disagree; 4 = agree; 5 =strongly agree. Questions 2 and 4 were scored reversely. The questionnaire was given in printed form at discharge, and the responses were collected by telephone call the day after the procedure.
Sample size estimation and statistical analyses The primary endpoint of the study was the occurrence of major desaturation events (i.e., SpO2 <80% with nasal oxygen supply 2 L/min). Assuming a desaturation rate of 20 ± 5%, we calculated a lower critical number of 25 patients per group to prove non-inferiority within the above limits of the primary endpoint, with a p-value of <0.05 and 85% power.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Attica
-
Athens, Attica, Greece, 15561
- Naval Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients scheduled for flexible bronchoscopy at the Naval Hospital of Athens
- Written informed consent
Exclusion Criteria:
- known or suspected allergy to any of the study drugs
- renal impairment (serum creatinine > 2 mg/dL)
- hepatic impairment (liver enzymes > 2 times the upper limit of normal)
- seizure disorders
- history of psychosis or bipolar disorder
- hemodynamic instability (heart rate - HR < 50 bpm or systolic blood pressure - SBP < 90 mmHg)
- critically ill patients.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: DK group
Dexmedetomidine solution of 1 μg/kg dissolved in 60 ml saline was administered over 15 minutes, followed by a maintenance dose of 0.5 μg/kg/h (continuous infusion).
After the first 15 minutes, a bolus dose of 50 mg ketamine dissolved in 10 ml saline was given.
|
Dexmedetomidine solution of 1 μg/kg dissolved in 60 ml saline was administered over 15 minutes, followed by a maintenance dose of 0.5 μg/kg/h (continuous infusion).
Other Names:
A bolus dose of 50 mg ketamine dissolved in 10 ml saline was given 15 minutes after Dexmedetomidine initiation.
Other Names:
|
Active Comparator: MF group
Bolus doses of midazolam (5 mg midazolam dissolved in 10 ml saline; 2 ml of the solution or 1 mg midazolam per bolus, premedication dose of 2mg, induction dose of 2 mg) and fentanyl (100 μg / 10 ml; 5 ml of the solution or 50 μg fentanyl per bolus, induction dose of 50μg) were administered at 20-minute intervals in between and titrated as needed to obtain the desired sedation depth.
No more than 12 mg of midazolam and 150 μg of fentanyl were administered.
|
Bolus doses of midazolam (5 mg midazolam dissolved in 10 ml saline; 2 ml of the solution or 1 mg midazolam per bolus, premedication dose of 2mg, induction dose of 2 mg) were administered at 20-minute intervals in between and titrated as needed to obtain the desired sedation depth.
No more than 12 mg of midazolam were administered.
Other Names:
Bolus doses of fentanyl (100 μg / 10 ml; 5 ml of the solution or 50 μg fentanyl per bolus, induction dose of 50μg) were administered at 20-minute intervals in between and titrated as needed to obtain the desired sedation depth.
No more than 150 μg of fentanyl were administered.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Depth of sedation Ramsay
Time Frame: Minute 10 of procedure
|
Assessed by Ramsay sedation scale that divides a patient's level of sedation into six categories ranging from severe agitation to deep coma.
(https://www.msdmanuals.com/professional/multimedia/table/the-ramsay-sedation-scale;
doi:10.1136/bmj.2.5920.656)
|
Minute 10 of procedure
|
Depth of sedation Ramsay
Time Frame: Minute 20 of procedure
|
Assessed by Ramsay sedation scale that divides a patient's level of sedation into six categories ranging from severe agitation to deep coma.
(https://www.msdmanuals.com/professional/multimedia/table/the-ramsay-sedation-scale;
doi:10.1136/bmj.2.5920.656)
|
Minute 20 of procedure
|
Depth of sedation Ramsay
Time Frame: Minute 30 of procedure
|
Assessed by Ramsay sedation scale that divides a patient's level of sedation into six categories ranging from severe agitation to deep coma.
(https://www.msdmanuals.com/professional/multimedia/table/the-ramsay-sedation-scale;
doi:10.1136/bmj.2.5920.656)
|
Minute 30 of procedure
|
Depth of sedation Ramsay
Time Frame: Minute 40 of procedure
|
Assessed by Ramsay sedation scale that divides a patient's level of sedation into six categories ranging from severe agitation to deep coma.
(https://www.msdmanuals.com/professional/multimedia/table/the-ramsay-sedation-scale;
doi:10.1136/bmj.2.5920.656)
|
Minute 40 of procedure
|
Depth of sedation Ramsay
Time Frame: Minute 50 of procedure
|
Assessed by Ramsay sedation scale that divides a patient's level of sedation into six categories ranging from severe agitation to deep coma.
(https://www.msdmanuals.com/professional/multimedia/table/the-ramsay-sedation-scale;
doi:10.1136/bmj.2.5920.656)
|
Minute 50 of procedure
|
Depth of sedation Ramsay
Time Frame: Minute 60 of procedure
|
Assessed by Ramsay sedation scale that divides a patient's level of sedation into six categories ranging from severe agitation to deep coma.
(https://www.msdmanuals.com/professional/multimedia/table/the-ramsay-sedation-scale;
doi:10.1136/bmj.2.5920.656)
|
Minute 60 of procedure
|
Depth of sedation Ramsay
Time Frame: Minute 70 of procedure
|
Assessed by Ramsay sedation scale that divides a patient's level of sedation into six categories ranging from severe agitation to deep coma.
(https://www.msdmanuals.com/professional/multimedia/table/the-ramsay-sedation-scale;
doi:10.1136/bmj.2.5920.656)
|
Minute 70 of procedure
|
Depth of sedation Ramsay
Time Frame: Minute 80 of procedure
|
Assessed by Ramsay sedation scale that divides a patient's level of sedation into six categories ranging from severe agitation to deep coma.
(https://www.msdmanuals.com/professional/multimedia/table/the-ramsay-sedation-scale;
doi:10.1136/bmj.2.5920.656)
|
Minute 80 of procedure
|
Depth of sedation Ramsay
Time Frame: Minute 90 of procedure
|
Assessed by Ramsay sedation scale that divides a patient's level of sedation into six categories ranging from severe agitation to deep coma.
(https://www.msdmanuals.com/professional/multimedia/table/the-ramsay-sedation-scale;
doi:10.1136/bmj.2.5920.656)
|
Minute 90 of procedure
|
Depth of sedation Riker
Time Frame: Minute 10 of procedure
|
Assessed by Riker's Sedation-Agitation Scale that ranges from 1 to 7, with scores of <4 indicating deeper sedation, a score of 4 indicating an appearance of calm and cooperativeness, and scores of ≥5 indicating increasing agitation.
(https://www.msdmanuals.com/professional/multimedia/table/riker-sedation-agitation-scale;
Crit Care Med.
1999;27:1325-1329)
|
Minute 10 of procedure
|
Depth of sedation Riker
Time Frame: Minute 20 of procedure
|
Assessed by Riker's Sedation-Agitation Scale that ranges from 1 to 7, with scores of <4 indicating deeper sedation, a score of 4 indicating an appearance of calm and cooperativeness, and scores of ≥5 indicating increasing agitation.
(https://www.msdmanuals.com/professional/multimedia/table/riker-sedation-agitation-scale;
Crit Care Med.
1999;27:1325-1329)
|
Minute 20 of procedure
|
Depth of sedation Riker
Time Frame: Minute 30 of procedure
|
Assessed by Riker's Sedation-Agitation Scale that ranges from 1 to 7, with scores of <4 indicating deeper sedation, a score of 4 indicating an appearance of calm and cooperativeness, and scores of ≥5 indicating increasing agitation.
(https://www.msdmanuals.com/professional/multimedia/table/riker-sedation-agitation-scale;
Crit Care Med.
1999;27:1325-1329)
|
Minute 30 of procedure
|
Depth of sedation Riker
Time Frame: Minute 40 of procedure
|
Assessed by Riker's Sedation-Agitation Scale that ranges from 1 to 7, with scores of <4 indicating deeper sedation, a score of 4 indicating an appearance of calm and cooperativeness, and scores of ≥5 indicating increasing agitation.
(https://www.msdmanuals.com/professional/multimedia/table/riker-sedation-agitation-scale;
Crit Care Med.
1999;27:1325-1329)
|
Minute 40 of procedure
|
Depth of sedation Riker
Time Frame: Minute 50 of procedure
|
Assessed by Riker's Sedation-Agitation Scale that ranges from 1 to 7, with scores of <4 indicating deeper sedation, a score of 4 indicating an appearance of calm and cooperativeness, and scores of ≥5 indicating increasing agitation.
(https://www.msdmanuals.com/professional/multimedia/table/riker-sedation-agitation-scale;
Crit Care Med.
1999;27:1325-1329)
|
Minute 50 of procedure
|
Depth of sedation Riker
Time Frame: Minute 60 of procedure
|
Assessed by Riker's Sedation-Agitation Scale that ranges from 1 to 7, with scores of <4 indicating deeper sedation, a score of 4 indicating an appearance of calm and cooperativeness, and scores of ≥5 indicating increasing agitation.
(https://www.msdmanuals.com/professional/multimedia/table/riker-sedation-agitation-scale;
Crit Care Med.
1999;27:1325-1329)
|
Minute 60 of procedure
|
Depth of sedation Riker
Time Frame: Minute 70 of procedure
|
Assessed by Riker's Sedation-Agitation Scale that ranges from 1 to 7, with scores of <4 indicating deeper sedation, a score of 4 indicating an appearance of calm and cooperativeness, and scores of ≥5 indicating increasing agitation.
(https://www.msdmanuals.com/professional/multimedia/table/riker-sedation-agitation-scale;
Crit Care Med.
1999;27:1325-1329)
|
Minute 70 of procedure
|
Depth of sedation Riker
Time Frame: Minute 80 of procedure
|
Assessed by Riker's Sedation-Agitation Scale that ranges from 1 to 7, with scores of <4 indicating deeper sedation, a score of 4 indicating an appearance of calm and cooperativeness, and scores of ≥5 indicating increasing agitation.
(https://www.msdmanuals.com/professional/multimedia/table/riker-sedation-agitation-scale;
Crit Care Med.
1999;27:1325-1329)
|
Minute 80 of procedure
|
Depth of sedation Riker
Time Frame: Minute 90 of procedure
|
Assessed by Riker's Sedation-Agitation Scale that ranges from 1 to 7, with scores of <4 indicating deeper sedation, a score of 4 indicating an appearance of calm and cooperativeness, and scores of ≥5 indicating increasing agitation.
(https://www.msdmanuals.com/professional/multimedia/table/riker-sedation-agitation-scale;
Crit Care Med.
1999;27:1325-1329)
|
Minute 90 of procedure
|
Bronchoscopist satisfaction
Time Frame: 1 hour after the end of the procedure
|
Bronchoscopist satisfaction was measured with a Likert-scale tool answering the question "How satisfied are you with both the ease and outcome of the procedure?"
as follows: 1 = not satisfied at all; 2 = somewhat satisfied; 3 = more satisfied with the procedural outcome; 4 = mostly satisfied with the outcome and somewhat with procedural ease; 5 = exceptionally satisfied with both procedural outcome and ease.
|
1 hour after the end of the procedure
|
Patient satisfaction
Time Frame: 24 hours after bronchoscopy
|
Patient satisfaction was evaluated by a short, custom-made questionnaire that included the following questions: 1) I was satisfied with the sedation administered for the procedure, 2) I felt pain and/or discomfort beyond my tolerance during the procedure, 3) I believe my needs were met during the procedure 4) I felt pain and discomfort after the procedure, 5) I would be willing to undergo a second procedure if the first did not yield adequate results.
The responses were measured in a Likert scale format with values 1 = strongly disagree; 2 = disagree; 3 = neither agree nor disagree; 4 = agree; 5 =strongly agree.
Questions 2 and 4 were scored reversely.
|
24 hours after bronchoscopy
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Sotirios Fouzas, MD, PhD, University of Patras
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Lung Diseases
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Anesthetics, Dissociative
- Anesthetics, Intravenous
- Anesthetics, General
- Anesthetics
- Excitatory Amino Acid Antagonists
- Excitatory Amino Acid Agents
- Analgesics, Non-Narcotic
- Adrenergic alpha-2 Receptor Agonists
- Adrenergic alpha-Agonists
- Adrenergic Agonists
- Analgesics, Opioid
- Narcotics
- Tranquilizing Agents
- Psychotropic Drugs
- Hypnotics and Sedatives
- Adjuvants, Anesthesia
- Anti-Anxiety Agents
- GABA Modulators
- GABA Agents
- Ketamine
- Fentanyl
- Midazolam
- Dexmedetomidine
Other Study ID Numbers
- DKvFM
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lung Diseases
-
Aveiro UniversityFundação para a Ciência e a TecnologiaNot yet recruitingInterstitial Lung DiseasesPortugal
-
RWTH Aachen UniversityCompletedObstructive Lung DiseasesGermany
-
Guangzhou Institute of Respiratory DiseaseUnknownInterstitial Lung Disease | Transbronchial Lung Cryobiopsy | Surgical Lung Biopsy
-
China-Japan Friendship HospitalXiangya Hospital of Central South University; Peking Union Medical College... and other collaboratorsUnknown
-
Academisch Medisch Centrum - Universiteit van Amsterdam...CompletedInterstitial Lung DiseasesNetherlands
-
Centre Hospitalier Universitaire de Saint EtienneCompleted
-
Bastiaan DriehuysNational Heart, Lung, and Blood Institute (NHLBI); University of Iowa; Children... and other collaboratorsRecruitingInterstitial Lung DiseasesUnited States
-
Shanghai East HospitalRegend TherapeuticsCompletedInterstitial Lung DiseasesChina
-
Aveiro UniversityFundação para a Ciência e a Tecnologia; Centro Hospitalar do Baixo VougaRecruitingInterstitial Lung Diseases (ILD)Portugal
-
China-Japan Friendship HospitalNot yet recruitingTransbronchial Lung Cryobiopsy
Clinical Trials on Dexmedetomidine
-
Cairo UniversityUnknownSpinal Anesthesia DurationEgypt
-
Guangzhou Women and Children's Medical CenterCompletedAmbulatory Surgical ProceduresChina
-
The First Affiliated Hospital with Nanjing Medical...CompletedPostoperative Pain | Breast Feeding | Analgesia ObstetricalChina
-
Seoul National University Bundang HospitalCompleted
-
Guangzhou General Hospital of Guangzhou Military...CompletedPharmacodynamic InteractionChina
-
University Hospital DubravaRecruitingAortic Valve Stenosis | Systemic Inflammatory ResponseCroatia
-
Guangzhou General Hospital of Guangzhou Military...Completed
-
First Affiliated Hospital, Sun Yat-Sen UniversityUnknownArteriovenous MalformationChina
-
Guangzhou General Hospital of Guangzhou Military...UnknownCombined Spinal-epidural AnesthesiaChina
-
National Cancer Institute, EgyptCompleted